“A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial”, J Infect Dis, vol. 203, pp. 1396-1404, 2011.
, “A SARS DNA Vaccine Induces Neutralizing Antibody and Cellular Immune Responses in Healthy Adults in a Phase I Clinical Trial”, Vaccine, vol. 26, pp. 6338-6343, 2008.
, “Safety, Immunogenicity and Efficacy of Modified Vaccinia Ankara (MVA) Against Dryvax Challenge in Vaccinia-Naive and Vaccinia-Immune Individuals”, Vaccine, vol. 25, pp. 1513-1525, 2007.
, “A Replication Defective Recombinant Ad5 Vaccine Expressing Ebola Virus GP is Safe and Immunogenic in Healthy Adults”, Vaccine, vol. 29, pp. 304-313, 2010.
, “Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-cell Responses”, PLoS One, vol. 5, p. e9015, 2010.
“Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect”, J Infect Dis, vol. 208, pp. 418-422, 2013.
, “Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (i.m.), Subcutaneous (s.c.) and Intradermal (i.d.) Administration (VRC 011)”, PLoS ONE, vol. 9, p. e91366, 2014.
, “Phase I Clinical Evaluation of a Six-Plasmid Multiclade HIV-1 DNA Candidate Vaccine”, Vaccine, vol. 25, pp. 4085-4092, 2007.
, “Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine”, J Infect Dis, vol. 194, pp. 1650-1660, 2006.
, “Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector”, J Infect Dis, vol. 194, pp. 1638-1649, 2006.
, “Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses Despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial”, PLoS One, vol. 9, p. e106240, 2014.
, “DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-cell Responses After rAd5 Boost in a Randomized Clinical Trial”, PLoS One, vol. 8, p. e59340, 2013.
, “DNA Priming and Influenza Vaccine Immunogenicity: Two Phase 1 Open Label Randomised Clinical Trials”, Lancet Infect Dis, vol. 11, pp. 916-924, 2011.
,